CP-690,550
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End-Stage Renal Disease
Conditions
End-Stage Renal Disease, Hemodialysis
Trial Timeline
Feb 1, 2003 → Jun 1, 2003
NCT ID
NCT01710020About CP-690,550
CP-690,550 is a phase 1 stage product being developed by Pfizer for End-Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01710020. Target conditions include End-Stage Renal Disease, Hemodialysis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01101919 | Phase 1 | Completed |
| NCT01185184 | Phase 1 | Completed |
| NCT00661661 | Phase 3 | Completed |
| NCT00414661 | Pre-clinical | Completed |
| NCT01710020 | Phase 1 | Completed |
Competing Products
20 competing products in End-Stage Renal Disease